Skip to Main Content

Author Archives: Daniel Hougendobler

12.06.13

Recap: “The Global Fund 2014-2016: Sustaining the Fight Against AIDS, Tuberculosis, and Malaria”

By Daniel Hougendobler

This week Washington, DC hosted the Fourth Global Fund Replenishment, which was followed by a half-day conference: “The Global Fund 2014-2016: Sustaining the Fight Against AIDS, Tuberculosis, and Malaria,” held at Georgetown University. While the Global Fund fell short of its $15 billion goal, the $12 billion pledged represents a 30% increase over its last […]

Categories:
Thematic Areas:

11.07.13

Good Riddance to U.S. Trans Fats

By Daniel Hougendobler

The Food and Drug Administration (FDA) has been subject to frequent criticism for its lax oversight of food safety, and particularly of food additives. However, this morning the agency stepped out ahead of most of its international peers, submitting for public comment a new determination that would effectively remove partially hydrogenated oils (PHOs), the primary […]

Categories:
Thematic Areas:

10.23.13

The Enduring Stigma of Mental Illness

By Daniel Hougendobler

The destigmatization of disease is among the most important public health achievements of the past century, one of the most dramatic examples of which can be seen with HIV and AIDS. In the early days of the epidemic, an HIV-positive status was linked with socially undesirable personal characteristics, e.g. homosexuality or Haitian ancestry, or “deviant” […]

Categories:
Tags:
Thematic Areas:

08.08.13

A New Frontier: The Access to Medicines Movement and NCDs

By Daniel Hougendobler

Ensuring access to medicines requires a two-pronged approach.  First, medicines must be invented and developed.  For conditions that widely affect both the rich and poor, this presents little problem.  Because those in the developed world can afford to pay large sums for these medicines, pharmaceutical companies have a strong financial incentive to develop treatments.  However, […]

Categories:
Tags:
Thematic Areas:

06.21.13

The End of “Pay-for-Delay”? By Opening Collusive Pharmaceutical Settlements to Antitrust Scrutiny, FTC v. Actavis Promises to Make Medicines More Affordable

By Daniel Hougendobler

  In a decision that could save U.S. consumers and taxpayers billions of dollars a year, the Supreme Court ruled Monday that “pay-for-delay,” also known as “reverse payment” settlements, between name-brand and generics pharmaceutical companies are subject to antitrust laws. The seeds of the controversy were planted in 1984 with the passage of the Hatch-Waxman […]

Thematic Areas:

06.07.13

A Surprising U.S. Intervention at the 66th World Health Assembly Breathes Life Into a Proposed WHO Biomedical R&D Treaty

By Daniel Hougendobler

For those hoping for a biomedical research and development treaty, the 2013 World Health Assembly (WHA) concluded with a glimmer of hope.  The WHA both called for greater study into current research and development trends and adopted an unexpected U.S. proposal to convene a series of advisory meetings, tasked with developing demonstration projects intended to […]

Categories:
Tags:
Thematic Areas:

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.